Results 301 to 310 of about 373,608 (350)

Tumor Angiogenesis Inhibitors

Biochemistry (Moscow), 2003
Formation of the blood supply system is a critical step in malignant transformation of neoplasms which results in the penetration of tumor cells into neighboring tissues and metastatic growth. Significant progress in the elucidation of mechanisms underlying tumor angiogenesis and the discovery of a great diversity of biomolecules involved in its ...
S M, Kiselev, S V, Lutsenko, S E, Severin, E S, Severin   +3 more
openaire   +2 more sources

Src Inhibitors and Angiogenesis

Current Pharmaceutical Design, 2007
Angiogenesis is a tightly regulated process that leads to the formation of new blood vessels in limited physiological conditions, and can also occur under pathological situations as retinopathies, arthritis, endometriosis and cancer. Enhanced angiogenesis is present in tumors that need new blood capillaries to grow, remove metabolic waste and transport
SCHENONE S, MANETTI, FABRIZIO, BOTTA, MAURIZIO   +2 more
openaire   +5 more sources

Inhibitors of Angiogenesis

2015
Angiogenesis plays a pivotal role in malignant, ischemic, inflammatory, infectious and immune disorders. The increasing molecular understanding of angiogenic processes fostered the development of strategies to induce or inhibit angiogenesis for therapeutic purposes.
H, Büning, U T, Hacker
openaire   +2 more sources

Update on angiogenesis inhibitors

Current Opinion in Oncology, 2005
A number of therapeutic agents have been developed which have anti-angiogenic potential. Here we present the most recent data from clinical trials with some of the promising inhibitors of angiogenesis.Agents that target the vascular endothelial growth factor signaling pathway are the furthest along in clinical development.
Anaadriana, Zakarija, Gerald, Soff
openaire   +2 more sources

Endogenous angiogenesis inhibitors

APMIS, 2004
When the FDA commissioner announced in February 2004 the approval of Avastin for the treatment of patients with colon cancer, he called angiogenesis inhibitors a fourth modality of anti‐cancer therapy. Because angiogenesis inhibitors are relatively less toxic than conventional chemotherapy and have a lower risk of drug resistance, they may also ...
openaire   +2 more sources

Endogenous Inhibitors of Angiogenesis

Cancer Research, 2005
Abstract Angiogenesis, the formation of new blood vessels, is required for many pathologic processes, including invasive tumor growth as well as physiologic organ/tissue maintenance. Angiogenesis during development and adulthood is likely regulated by a balance between endogenous proangiogenic and antiangiogenic factors. It is speculated
Pia, Nyberg, Liang, Xie, Raghu, Kalluri
openaire   +2 more sources

Heparin Derivatives as Angiogenesis Inhibitors

Current Pharmaceutical Design, 2003
Angiogenesis is the process of generating new capillary blood vessels. Uncontrolled endothelial cell proliferation is observed in tumor neovascularization and in angioproliferative diseases. Tumors cannot growth as a mass above few mm(3) unless a new blood supply is induced. It derives that the control of the neovascularization process may affect tumor
PRESTA, Marco, LEALI, Daria, STABILE H., RONCA, Roberto, CAMOZZI M., COCO L., MORONI E., LIEKENS S., RUSNATI, Marco   +8 more
openaire   +2 more sources

Inhibitors of Tumor Angiogenesis

2008
Inhibitors of Tumor ...
Harris, Adrian L, GENERALI, DANIELE
openaire   +3 more sources

Angiogenesis Inhibitors May Regulate Adiposity

Nutrition Reviews, 2003
Overweight and obese are major health concerns owing to the complex co-morbidities that inevitably follow. Diet and exercise are the primary means by which people attempt to lose weight. A recent study in an obese mouse model suggested that angiogenesis inhibitors, which are designed to inhibit tumor growth, are able to reduce adipose tissue mass by ...
Liping, Liu, Mohsen, Meydani
openaire   +2 more sources

Angiozyme: A Novel angiogenesis inhibitor

Current Oncology Reports, 2001
Several inhibitors of angiogenesis are being developed for the treatment of cancer. One dominant strategy involves disruption of the vascular endothelial growth factor (VEGF) pathway by inhibition of the receptors for VEGF. Inhibition of the VEGF receptor activity can be accomplished using catalytic RNA molecules known as ribozymes, which downregulate ...
D E, Weng, N, Usman
openaire   +2 more sources